ERCC6L and neoplasm: In addition, ERCC6L silencing can lead to cycle arrest, proliferation inhibition, and reduced invasion of tumor cells in renal carcinoma, breast cancer, colorectal cancer, hepatocellular carcinoma, and non-small cell lung adenocarcinoma [9–13].